SkinBioTherapeutics PLC Cash Flow Conversion Efficiency
SkinBioTherapeutics PLC cash flow conversion efficiency. Based on the latest financial reports, SkinBioTherapeutics PLC (SBTX) has a cash flow conversion efficiency ratio of -0.053x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-494.84K ≈ $-60.21 USD) by net assets (GBX9.42 Million ≈ $1.15K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SkinBioTherapeutics PLC (2016–2025)
Cash flow conversion efficiency of SkinBioTherapeutics PLC from 2016 to 2025. This chart illustrates how SkinBioTherapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for SkinBioTherapeutics PLC for real-time trading data and today's change.
SkinBioTherapeutics PLC Cash Flow Conversion Ratio Explained
SkinBioTherapeutics PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SkinBioTherapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SkinBioTherapeutics PLC ranked by their cash flow conversion efficiency. Also see how much is SkinBioTherapeutics PLC worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Manx Financial Group Plc
LSE:MFX
|
-0.107x |
|
GETT Gold Inc
V:GETT
|
-0.004x |
|
Recon Technology Ltd
NASDAQ:RCON
|
-0.015x |
|
LIFT GLOBAL VENT. LS-01
F:7XO
|
N/A |
|
International Zeolite Corp
V:IZ
|
-0.053x |
|
XP Factory PLC
LSE:XPF
|
0.276x |
|
AA Mission Acquisition Corp.
NYSE:AAM
|
0.000x |
|
Subsea 7 SA
LSE:0OGK
|
-0.030x |
Annual Cash Flow Conversion Efficiency for SkinBioTherapeutics PLC (2016–2025)
The table below shows the annual cash flow conversion efficiency of SkinBioTherapeutics PLC from 2016 to 2025. Review SkinBioTherapeutics PLC leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX9.42 Million ≈ $1.15K |
GBX-1.30 Million ≈ $-157.94 |
-0.138x | +84.99% |
| 2024-06-30 | GBX2.97 Million ≈ $361.35 |
GBX-2.73 Million ≈ $-331.71 |
-0.918x | +30.77% |
| 2023-06-30 | GBX1.99 Million ≈ $242.72 |
GBX-2.65 Million ≈ $-321.84 |
-1.326x | -22.79% |
| 2022-06-30 | GBX2.48 Million ≈ $301.18 |
GBX-2.67 Million ≈ $-325.23 |
-1.080x | -262.16% |
| 2021-06-30 | GBX5.22 Million ≈ $634.55 |
GBX-1.56 Million ≈ $-189.20 |
-0.298x | +17.59% |
| 2020-06-30 | GBX2.47 Million ≈ $300.02 |
GBX-892.14K ≈ $-108.55 |
-0.362x | +3.51% |
| 2019-06-30 | GBX3.81 Million ≈ $463.58 |
GBX-1.43 Million ≈ $-173.82 |
-0.375x | -93.22% |
| 2018-06-30 | GBX3.44 Million ≈ $418.67 |
GBX-667.75K ≈ $-81.25 |
-0.194x | -34.11% |
| 2017-06-30 | GBX4.21 Million ≈ $512.66 |
GBX-609.70K ≈ $-74.18 |
-0.145x | -4733.88% |
| 2016-06-30 | GBX389.85K ≈ $47.43 |
GBX-1.17K ≈ $-0.14 |
-0.003x | -- |
About SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the sympt… Read more